- Medtronic’s 2027 adjusted earnings per share (EPS) forecast falls short of expectations, with a range of $5.90 to $6.00 versus an estimate of $6.06.
- The company anticipates organic revenue growth between 6.75% and 7.25% for 2027.
- For the fourth quarter, Medtronic reported adjusted EPS of $1.55, matching estimates but down from $1.62 year-over-year.
- Quarterly revenue reached $9.81 billion, a 9.9% increase year-over-year, surpassing the estimate of $9.64 billion.
- Cardiovascular segment revenue was $3.80 billion, a 14% rise year-over-year, exceeding expectations of $3.74 billion.
- The Medical Surgical segment reported $2.39 billion in revenue, an 8% increase year-over-year, above the estimated $2.3 billion.
- Revenue from the Neuroscience segment was $2.75 billion, a 5% increase year-over-year, slightly below the estimated $2.77 billion.
- Diabetes segment revenue stood at $837 million, achieving a 15% increase year-over-year and surpassing the estimate of $813.5 million.
- Overall organic revenue growth was 6.6%, compared to 5.4% the previous year, beating the estimate of 5.68%.
- The adjusted operating margin was 25.5%, down from 27.8% the previous year and below the estimated 27.1%.
- Analyst recommendations for the company include 17 buys, 14 holds, and no sells.
“`
Medtronic Plc on Smartkarma
Several analysts on Smartkarma, including Baptista Research, have been covering Medtronic Plc closely, providing insights on the company’s strategic moves and financial performance. Baptista Research‘s coverage includes reports on significant developments like Medtronic’s acquisitions and breakthroughs, such as the $650 million buyout of SPR Therapeutics to strengthen its chronic pain management portfolio.
Analysts have highlighted Medtronic’s strong revenue growth, with key drivers such as the Cardiovascular portfolio, particularly the Cardiac Ablation Solutions business. Medtronic’s potential acquisition of CathWorks, specializing in AI-driven coronary physiology assessment, is seen as a move to expand its interventional cardiology footprint. Overall, analyst sentiment leans bullish on Medtronic’s innovation and strategic acquisitions, positioning the company for growth in the medical technology sector.
A look at Medtronic Plc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Medtronic Plc, a company known for developing therapeutic and diagnostic medical products, has received a strong Smartkarma Smart Scores rating. With a solid Value score of 4 and a top-notch Dividend score of 5, Medtronic demonstrates strong financial performance and commitment to rewarding its investors. While the Growth and Resilience scores stand at 3, indicating room for improvement in expansion and risk management, the company’s Momentum score of 2 suggests a slightly slower pace in market performance. Overall, the mix of high Value and Dividend scores bodes well for Medtronic Plc‘s long-term prospects in the medical products industry.
Medtronic Plc‘s focus on developing a wide range of essential medical products, from heart management devices to pain and movement disorder solutions, positions it as a key player in the global healthcare market. The company’s Smartkarma Smart Scores highlight its solid fundamentals in terms of value and dividend, paving the way for continued success in the long run. With a strategic mix of innovative product offerings and a strong track record in the industry, Medtronic Plc holds promise for investors looking for stability and growth potential in the healthcare sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
